Chunlai Lu
Impact in
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Molecular Biology top 10%
- Circular RNAs in diseases
- RNA modifications and cancer
- Cancer-related gene regulation
- Ubiquitin and proteasome pathways
- Epigenetics and DNA Methylation
Papers in
-
- Epigenetics and DNA Methylation 4
- RNA modifications and cancer 4
- Ubiquitin and proteasome pathways 3
- Cancer-related gene regulation 3
-
- Ferroptosis and cancer prognosis 3
- Lung Cancer Diagnosis and Treatment 3
- Co-authors
- Jie Gu (22 shared papers)Fengkai Xu (24 shared papers)Di Ge (14 shared papers)Qiaoliang Zhu (11 shared papers)Di Ge (19 shared papers)Yiwei Chu (7 shared papers)Guangyin Zhao (8 shared papers)Zongwu Lin (6 shared papers)
- Journals
- Tumor Biology (4 papers)EBioMedicine (2 papers)PLoS ONE (2 papers)Journal of Cancer (2 papers)Cancer Letters (2 papers)
- Partner nations
- ChinaUnited StatesSingapore
In The Last Decade
Chunlai Lu
40 papers receiving 1.5k citations
Chunlai Lu's Hit Papers
Peers
Comparison fields: 5 of 84
- Cancer Research 423
- Molecular Biology 859
- Oncology 270
- Pulmonary and Respiratory Medicine 242
- Immunology 160
Countries citing papers authored by Chunlai Lu
This map shows the geographic impact of Chunlai Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chunlai Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chunlai Lu more than expected).
Fields of papers citing papers by Chunlai Lu
This network shows the impact of papers produced by Chunlai Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chunlai Lu. The network helps show where Chunlai Lu may publish in the future.
Co-authors
The 25 scholars most cited alongside Chunlai Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 42 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity Hit paper breakdown → | 2021 | 424 |
| 2 | 2018 | 99 | |
| 3 | 2012 | 97 | |
| 4 | 2011 | 95 | |
| 5 | 2022 | 84 | |
| 6 | 2013 | 82 | |
| 7 | 2013 | 73 | |
| 8 | 2014 | 70 | |
| 9 | 2008 | 50 | |
| 10 | 2018 | 50 | |
| 11 | 2015 | 38 | |
| 12 | 2022 | 31 | |
| 13 | 2020 | 30 | |
| 14 | 2016 | 29 | |
| 15 | 2018 | 28 | |
| 16 | 2015 | 27 | |
| 17 | 2023 | 25 | |
| 18 | 2015 | 25 | |
| 19 | 2021 | 23 | |
| 20 | Novel methylation-driven genes identified as prognostic indicators for lung squamous cell carcinoma. | 2019 | 17 |
About Chunlai Lu
Chunlai Lu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Surgery, Oncology and Cancer Research, having authored 42 papers that have together received 1.5k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (4 papers), RNA modifications and cancer (4 papers), Ferroptosis and cancer prognosis (3 papers), Ubiquitin and proteasome pathways (3 papers), Cancer-related gene regulation (3 papers), Lung Cancer Diagnosis and Treatment (3 papers), Esophageal Cancer Research and Treatment (3 papers) and Soft tissue tumor case studies (3 papers). The work is most often cited by research in Cancer Research (423 citations), Molecular Biology (859 citations), Oncology (270 citations), Pulmonary and Respiratory Medicine (242 citations) and Immunology (160 citations). Chunlai Lu has collaborated with scholars based in China, United States and Singapore. Frequent co-authors include Jie Gu, Fengkai Xu, Di Ge, Qiaoliang Zhu, Di Ge, Yiwei Chu, Guangyin Zhao, Zongwu Lin, Yuanyuan Lv and Siying Wang. Their work appears in journals such as Tumor Biology, EBioMedicine, PLoS ONE, Journal of Cancer and Cancer Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.